Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Cash & Equivalents (2016 - 2025)

SRx Health Solutions' Cash & Equivalents history spans 13 years, with the latest figure at $1.3 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 1134.91% year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, up 1134.91%, while the annual FY2025 figure was $1.3 million, N/A changed from the prior year.
  • Cash & Equivalents reached $1.3 million in Q3 2025 per SRXH's latest filing, up from $912000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $26.0 million in Q3 2021 to a low of $106000.0 in Q3 2024.
  • Average Cash & Equivalents over 5 years is $6.5 million, with a median of $3.8 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: surged 4526.64% in 2021, then crashed 97.21% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $21.7 million in 2021, then plummeted by 56.4% to $9.5 million in 2022, then tumbled by 52.97% to $4.5 million in 2023, then crashed by 31.18% to $3.1 million in 2024, then crashed by 57.31% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Cash & Equivalents are $1.3 million (Q3 2025), $912000.0 (Q2 2025), and $1.1 million (Q1 2025).